Share

April 2016; 3 (2) ArticleOpen Access

Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis

Imke Metz, Tim Beißbarth, David Ellenberger, Florence Pache, Lidia Stork, Marius Ringelstein, Orhan Aktas, Sven Jarius, Brigitte Wildemann, Hassan Dihazi, Tim Friede, Wolfgang Brück, Klemens Ruprecht, Friedemann Paul
First published February 2, 2016, DOI: https://doi.org/10.1212/NXI.0000000000000204
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
972

Share

Article Information

vol. 3 no. 2 e204
DOI: 
https://doi.org/10.1212/NXI.0000000000000204
PubMed: 
26894206
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received October 14, 2015
  • Accepted in final form December 15, 2015
  • First Published February 2, 2016.
Copyright & Usage: 
© 2016 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Imke Metz, MD*,
    2. Tim Beißbarth, PhD*,
    3. David Ellenberger,
    4. Florence Pache, MD,
    5. Lidia Stork,
    6. Marius Ringelstein, MD,
    7. Orhan Aktas, MD,
    8. Sven Jarius, MD,
    9. Brigitte Wildemann, MD,
    10. Hassan Dihazi, PhD,
    11. Tim Friede, PhD,
    12. Wolfgang Brück, MD,
    13. Klemens Ruprecht, MD‡ and
    14. Friedemann Paul, MD‡
  1. Imke Metz, MD*,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. 1)commercial: speaker honoraria, travel grants from BiogenIdec, Bayer Healthcare, TEVA, Serono, Novartis

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. research grant from BiogenIdec.

    Research Support, Government Entities:

    1. grants from German Ministry for Education and Research (BMBF, ??German Competence Network Multiple Sclerosis?? (KKNMS), Pattern MS/NMO);

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Tim Beißbarth, PhD*,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. David Ellenberger,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Florence Pache, MD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Commercial: Travel grant from Genzyme, a Sanofi Company (2) Commercial: Travel grant from Bayer (3) Commercial: Travel grant from Biogene Idec (4) Non-profit: Travel grant from ECTRIMS ( European Committee for Treatment and Research in Multiple Sclerosis)

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) governmental grant to Friedemann Paul- used for 50 % of my employment: KKNMS- Bundesministerium f?r Bildung und Forschung-governmental support- Ministry in Germany (“) commercial grant to Friedemann Paul- used for a short time part employment to me: Novartis-no significant conflict of interest

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Lidia Stork,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Marius Ringelstein, MD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. 1. Novartis, funding for speaking at a confeence. 2. Bayer Schering, funding for travel to a conference. 3. Biogen Idec, funding for travel to a conference. 4. Genzyme, funding for travel to a conference.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Orhan Aktas, MD,
    8. Scientific Advisory Boards:

    1. (1) Medimmune Scientific Advisory Board

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Bayer, travel and speaker honoraria (2) Novartis, travel and speaker honoraria (3) Biogen, travel and speaker honoraria (4) Merck, travel and speaker honoraria (5) Serono, travel and speaker honoraria (6) Teva, travel and speaker honoraria (7) Genzyme, travel and speaker honoraria

    Editorial Boards:

    1. (1) PLoS ONE, Academic Editor, since 2012

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Novartis

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Novartis (2) Bayer (3) Biogen

    Research Support, Government Entities:

    1. (1) German Research Foundation (DFG), SFB974 (2) German Research Foundation (DFG), GRK1033 (3) German Ministry of Science (BMBF), EU-FP7

    Research Support, Academic Entities:

    1. (1) German Research Foundation (DFG)

    Research Support, Foundations and Societies:

    1. (1) Heinrich and Erna Schaufler-Foundation (2) Walter and Ilse Rose-Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Sven Jarius, MD,
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Brigitte Wildemann, MD,
    10. Scientific Advisory Boards:

    1. Brigitte Wildemann served on scientific advisory boards for Novartis

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Brigitte Wildemann has received funding for travel and speaker honoraria from Bayer Healthcare, Biogen, Merck Serono, Genzyme,a Sanofi Company, Novartis Pharmaceuticals, and Teva Pharma

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Brigitte Wildemann has has received research support from Biogen Idec, Biotest, Merck Serono, Novartis Pharmaceuticals, Teva Pharma, the Dietmar-Hopp-Foundation, and the German Ministry of Education and Research (BMBF)

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Hassan Dihazi, PhD,
    11. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  11. Tim Friede, PhD,
    12. Scientific Advisory Boards:

    1. (1) Biogen (2) Novartis (3) Bayer (4) Janssen (5) Gr?nenthal

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1) Biometrical Journal, Editor, 2009-2011 (2) Biometrical Journal, Associate Editor, since 2012 (3) BMC Medical Research Methodology, since 2011 (4) PLoS ONE, Academic Editor, 2013-2015 (5) PLoS ONE, Section Editor, since 2015

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Novartis Pharma AG, consultant, since 2007 (2) Pharmalog Institut f?r Klinische Forschung GmbH, consultant, since 2006 (3) Biogen Idec, consultant, 2012-2013 (4) Bayer, consultant, since 2015

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) Deutsche Forschungsgemeinschaft, Principal investigator, FR-3070/1-1, 2012-2016 (2) Bundesministerium f?r Bildung und Forschung, Principal investigator, 13 6406 0, 2011-2015 (3) Executive Agency for Health and Consumers, Principal investigator, 2010 12 13, 2011-2014 (4) Bundesministerium f?r Bildung und Forschung, Principal investigator, 13 6442 0, 2013-2016 (5) EU's 7th Framework Programme for research, technological development and demonstration, Principal investigator, FP HEALTH 2013 ? 602144, 2014-2017

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  12. Wolfgang Brück, MD,
    13. Scientific Advisory Boards:

    1. I serve on the advisory board of Genzyme, Novartis, Biogen Idec Germany and Teva Pharma.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. I received honoraria for oral presentations from Teva, Sanofi, Genzyme, Novartis, Merck-Serono, Biogen and Bayer in the last 2 years.

    Editorial Boards:

    1. I am editorial board member of Acta neuropathologica, Therapeutic Advances in Neurological disorders, Multiple Sclerosis International and Neuropathology and Applied Neurobiology

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. German Research foundation (DFG SFB TR43): The brain as atarget of inflammatory processes, 2008-2015German ministry for science and education: Competencenetwork multiple sclerosis, 2010-2015

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Tschira Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  13. Klemens Ruprecht, MD‡ and
    14. Scientific Advisory Boards:

    1. (1)sanofi-aventis/Genzyme (2)Novartis (3)Roche

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1)Bayer Healthcare, travel and speaker honoraria (2)Biogen Idec, travel and speaker honoraria (3)Merck Serono, travel and speaker honoraria (4)sanofi-aventis/Genzyme, travel and speaker honoraria (5)Teva Pharmaceuticals, travel and speaker honoraria (6)Novartis, travel and speaker honoraria (7)Guthy Jackson Charitable Foundation, travel honoraria

    Editorial Boards:

    1. (1) PLOS ONE, Academic Editor, since 2013

    Patents:

    1. NONE

    Publishing Royalties:

    1. (1) Neurologie in Frage und Antwort, Elsevier, 2000-2015

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Novartis

    Research Support, Government Entities:

    1. (1)German Ministry of Education and Research (BMBF/KKNMS, Competence Network Multiple Sclerosis)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  14. Friedemann Paul, MD‡
    15. Scientific Advisory Boards:

    1. Novartis OCTIMS study steering committee MedImmune steering committee

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. speaker honoraria and travel grants from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, and Merck Serono

    Editorial Boards:

    1. Academic Editor, PLoS ONE Associate Editor, Neurology Neuroimmunology and Neuroinflammation

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. consultancies for SanofiGenzyme, BiogenIdec, MedImmune

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research support from from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, and Merck Serono

    Research Support, Government Entities:

    1. German Research Council (DFG Exc 257), Werth Stiftung of the City of Cologne, German Ministry of Education and Research (BMBF Competence Network Multiple Sclerosis), Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program (combims.eu)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation, National Multiple Sclerosis Society of the USA

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Departments of Neuropathology (I.M., L.S., W.B.), Medical Statistics (T.B., D.E., T.F.), and Nephrology and Rheumatology, Internal Medicine (H.D.), University Medical Center Göttingen; Department of Neurology (F. Pache, K.R., F. Paul) and Clinical and Experimental Multiple Sclerosis Research Center (F. Pache, K.R., F. Paul), Charité–Universitätsmedizin Berlin; NeuroCure Clinical Research Center and Experimental and Clinical Research Center (F. Pache, F. Paul), Max Delbrueck Center for Molecular Medicine; Department of Neurology (M.R., O.A.), Medical Faculty, Heinrich-Heine-University Düsseldorf; and Molecular Neuroimmunology Group, Department of Neurology (S.J., B.W.), University of Heidelberg, Germany.
  1. Correspondence to Dr. Brück: wbrueck{at}med.uni-goettingen.de
View Full Text

Article usage

Article usage: February 2016 to September 2021

AbstractFullPdfSource
Feb 201648824164Highwire
Feb 201604518pmc
Mar 20163442939Highwire
Mar 201607034pmc
Apr 20162674140Highwire
Apr 201604518pmc
May 20168735922Highwire
May 201603927pmc
Jun 2016883116Highwire
Jun 201602512pmc
Jul 2016511115Highwire
Jul 20160158pmc
Aug 2016591612Highwire
Aug 201601810pmc
Sep 20163878Highwire
Sep 201601912pmc
Oct 201635710Highwire
Oct 20160227pmc
Nov 20163368Highwire
Nov 20160257pmc
Dec 201631113Highwire
Dec 2016095pmc
Jan 201748194Highwire
Jan 20170178pmc
Feb 2017321610Highwire
Feb 20170188pmc
Mar 201725407Highwire
Mar 20170165pmc
Apr 201716244Highwire
Apr 20178117pmc
May 201721152Highwire
May 201791011pmc
Jun 201725168Highwire
Jun 2017433pmc
Jul 201711132Highwire
Jul 201741211pmc
Aug 201711114Highwire
Aug 2017298pmc
Sep 201720919Highwire
Sep 201741014pmc
Oct 201711124Highwire
Oct 201731015pmc
Nov 201721162Highwire
Nov 201731513pmc
Dec 20179236Highwire
Jan 201820322Highwire
Feb 20184224Highwire
Mar 20189524Highwire
Apr 20187536Highwire
Apr 2018398pmc
May 201821515Highwire
Jun 201864910Highwire
Jun 2018078pmc
Jul 20189477Highwire
Aug 20183526Highwire
Aug 201841415pmc
Sep 20184513Highwire
Oct 201813527Highwire
Nov 20184448Highwire
Dec 201832643Highwire
Jan 2019102416Highwire
Feb 2019111427Highwire
Mar 2019115515Highwire
Apr 2019133718Highwire
May 2019187014Highwire
Jun 2019219816Highwire
Jul 2019165110Highwire
Aug 2019133414Highwire
Sep 201913427Highwire
Oct 20199475Highwire
Nov 201947713Highwire
Dec 2019112510Highwire
Jan 20202256Highwire
Feb 20201113Highwire
Mar 202062116Highwire
Apr 20205226Highwire
May 20201187Highwire
Jun 20206196Highwire
Jul 20201201Highwire
Aug 20203155Highwire
Sep 202092195Highwire
Oct 202038914Highwire
Nov 202012312Highwire
Dec 202042414Highwire
Jan 2021234420Highwire
Feb 202110205Highwire
Mar 20219363Highwire
Apr 20219317Highwire
May 202142210Highwire
Jun 20214185Highwire
Jul 202173410Highwire
Aug 20213277Highwire
Sep 20213219Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Alert Me

Advertisement